Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Pharming Acquires Patent Portfolio of PPL Therapeutics

By Pharmaceutical Processing | August 24, 2004

LEIDEN, The Netherlands (August 23 2004) – Pharming Group N.V. announced that it has acquired the patent portfolio of PPL Therapeutics Ltd .The company has acquired these patents to strengthen its product pipeline and protein production technology. Pharming has obtained patents and licenses on various products and technologies, including the production and purification of recombinant human fibrinogen and recombinant tissue sealant compositions. In addition, the company has obtained access to processes and know-how for the large scale GMP-grade purification of recombinant human fibrinogen.

“We are pleased to be able to strengthen our recombinant fibrinogen and recombinant tissue sealant products by acquiring PPL patents and processes, which saves the company time and resources in the development of these products.” said Dr. Francis Pinto, CEO of Pharming. “In addition, this transaction significantly advances the worldwide patent position of our protein production technology along with recent agreements with Infigen and ProBio and will allow the Company to actively pursue licensing and partnering opportunities.”

Pharming has also acquired patents on the production of recombinant protein products and production technology patents for proteins, fusion proteins, as well as peptides. The patents cover the production of several recombinant proteins, including Alpha-1-Antitrypsin, Factor IX, and others.

In addition, Pharming has taken over certain product and technology licenses that PPL had obtained from third parties.PPL had established this portfolio over a period of more than 15 years, but recently decided to restructure its commercial focus following a sale of the company. The financial terms of the transaction were not disclosed.Pharming Group N.V. products include potential treatments for genetic disorders and specialty products for surgical indications.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE